HOME >> BIOLOGY >> NEWS
Reducing sodium leads to substantial drop in blood pressure, finds NHLBI study

Sodium reduction combined with either a typical U.S. diet or the DASH diet, which is rich in vegetables, fruit, and low-fat dairy products and low in total and saturated fat, substantially lowered blood pressure in persons with high blood pressure and persons with higher than optimal blood pressure, according to the results of a study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

The DASH-Sodium study found that the lowest blood pressure levels were in those eating sodium levels much lower than the currently recommended maximum of 2,400 milligrams a day while also eating the DASH (Dietary Approaches to Stop Hypertension) diet. In both the DASH diet and a typical American diet, the lower the sodium, the lower the blood pressure. The combination of following the DASH diet at the lower sodium level reduced blood pressure more than either the DASH diet or lower sodium intake alone.

These findings, which are published in the January 4 issue of the New England Journal of Medicine, were initially reported in May 2000 at the annual meeting of the American Society of Hypertension.

The DASH-Sodium study lays to rest the long-standing controversy over whether sodium reduction lowers blood pressure in people who do not have hypertension, more commonly called high blood pressure. The study also has important implications for the treatment of hypertension, which affects almost 50 million people in this country, says NHLBI Director Dr. Claude Lenfant.

These results challenge Americans to eat the DASH diet and to reduce sodium consumption and the food industry to reduce sodium levels in foods. Meeting this challenge, along with other lifestyle changes, could prevent the rise of blood pressure with age and allow patients to control their hypertension with fewer or even no drugs, adds Dr. Lenfant.

In the DASH-Sodium study, 412 people were randomly assigned to eat
'"/>

Contact: NHLBI Communications Office
301-496-4236
NIH/National Heart, Lung, and Blood Institute
3-Jan-2001


Page: 1 2 3 4 5

Related biology news :

1. Reducing allergens in the home helps inner-city children with asthma
2. Reducing the risk of frost damage to short-season crops
3. Reducing primary chemical emissions does not always reduce pollution
4. Reducing methane emissions could lower overall abatement costs
5. Reducing VOC: new polymer coating process combines high degree of flexibility with improved environmental properties
6. Discovery By Fertility Specialist Offers Promise Of Reducing Multiple BirthsTied To Fertility Treatment
7. New Chemical Processing Technique Being Studied At UW May Hold Key To CleaningUp Hanford, Reducing Industrial Waste
8. NHLBI study finds DASH diet and reduced sodium lowers blood pressure for all
9. Sex differences in osmotic regulation of AVP and renal sodium handling
10. NHLBI study shows large blood pressure benefit from reduced dietary sodium
11. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction

Post Your Comments:
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: